CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
May 31, 2025 |
May 31, 2024 |
May 31, 2025 |
May 31, 2024 |
|
| Expenses | ||||
| Accounting and audit | $ 17,091 | $ 11,183 | $ 32,343 | $ 37,338 |
| Consulting | 8,250 | 53,274 | 43,818 | 143,332 |
| Fees and dues | 13,708 | 42,213 | 35,193 | 53,363 |
| Investor relations | 10,930 | 4,311 | 18,183 | 22,180 |
| Legal and professional | 14,101 | 14,396 | 29,693 | 56,628 |
| Office and miscellaneous | 15,022 | 15,577 | 54,426 | 50,829 |
| Mineral exploration costs | 9,161 | 7,080 | 23,124 | 57,444 |
| Research and development | 34,146 | 21,883 | 95,832 | 130,678 |
| Total expenses | 122,409 | 169,917 | 332,612 | 551,792 |
| Loss for the period before other items | (122,409) | (169,917) | (332,612) | (551,792) |
| Other income (expense) | ||||
| Foreign exchange gain (loss) | (7,955) | (1,417) | (4,840) | 786 |
| Realized gain (loss) on marketable securities | 0 | (243,560) | (352,239) | (969,873) |
| Realized foreign exchange gain (loss) on marketable securities | 0 | (14,451) | (17,133) | (53,474) |
| Unrealized gain (loss) on marketable securities | 0 | 161,362 | 377,803 | 742,493 |
| Unrealized foreign exchange gain (loss) on marketable securities | 0 | (19,918) | 0 | (13,373) |
| Net income (loss) for the period | (130,364) | (287,901) | (329,021) | (845,233) |
| Net income (loss) attributable to: | ||||
| Common shareholders | (130,364) | (287,849) | (328,952) | (844,759) |
| Non controlling interest | $ 0 | $ (52) | $ (69) | $ (474) |
| Basic income (loss) per share | $ (0.02) | $ (0.04) | $ (0.04) | $ (0.11) |
| Diluted income (loss) per share | $ (0.02) | $ (0.04) | $ (0.04) | $ (0.11) |
| Weighted average number of common shares outstanding - Basic | 8,019,394 | 7,758,305 | 7,846,447 | 7,758,305 |
| Weighted average number of common shares outstanding - Diluted | 8,019,394 | 7,758,305 | 7,846,447 | 7,758,305 |
| X | ||||||||||
- Definition Amount of marketable securities realized foreign exchange loss. No definition available.
|
| X | ||||||||||
- Definition Amount of marketable securities unrealized foreign exchange loss. No definition available.
|
| X | ||||||||||
- Definition Mineral exploration costs No definition available.
|
| X | ||||||||||
- Definition Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI). No definition available.
|
| X | ||||||||||
- Definition Amount of unrealized gain (loss) on investment in marketable security. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support. No definition available.
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|